Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 173

1.

Summaries for patients. The cost-effectiveness of strategies to prevent type 2 diabetes.

[No authors listed]

Ann Intern Med. 2005 Mar 1;142(5):I28. No abstract available.

PMID:
15738446
2.
3.

The cost-effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance.

Herman WH, Hoerger TJ, Brandle M, Hicks K, Sorensen S, Zhang P, Hamman RF, Ackermann RT, Engelgau MM, Ratner RE; Diabetes Prevention Program Research Group.

Ann Intern Med. 2005 Mar 1;142(5):323-32.

4.

Economic evaluation of therapeutic interventions to prevent Type 2 diabetes in Canada.

Caro JJ, Getsios D, Caro I, Klittich WS, O'Brien JA.

Diabet Med. 2004 Nov;21(11):1229-36.

PMID:
15498090
6.

Cost and clinical implications of diabetes prevention in an Australian setting: a long-term modeling analysis.

Palmer AJ, Tucker DM.

Prim Care Diabetes. 2012 Jul;6(2):109-21. doi: 10.1016/j.pcd.2011.10.006. Epub 2011 Dec 6.

PMID:
22153888
7.

Cost-effectiveness of sitagliptin-based treatment regimens in European patients with type 2 diabetes and haemoglobin A1c above target on metformin monotherapy.

Schwarz B, Gouveia M, Chen J, Nocea G, Jameson K, Cook J, Krishnarajah G, Alemao E, Yin D, Sintonen H.

Diabetes Obes Metab. 2008 Jun;10 Suppl 1:43-55. doi: 10.1111/j.1463-1326.2008.00886.x.

PMID:
18435673
8.

Clinical outcomes and cost-effectiveness of strategies for managing people at high risk for diabetes.

Eddy DM, Schlessinger L, Kahn R.

Ann Intern Med. 2005 Aug 16;143(4):251-64.

PMID:
16103469
9.

[Cost-effective analysis of preventive treatment on diabetes].

Hu Y, Chen SY, Wang JY.

Zhonghua Liu Xing Bing Xue Za Zhi. 2004 May;25(5):431-4. Chinese.

PMID:
15231174
10.

Cost-effectiveness and clinical outcomes of metformin or insulin add-on therapy in adults with type 2 diabetes.

Brown RR.

Am J Health Syst Pharm. 1998 Dec 15;55(24 Suppl 4):S24-7. No abstract available.

PMID:
9872692
11.

Summaries for patients. The cost-effectiveness of screening for type 2 diabetes.

[No authors listed]

Ann Intern Med. 2004 May 4;140(9):I29. No abstract available.

PMID:
15126270
12.

The economics of diabetes prevention.

Herman WH.

Med Clin North Am. 2011 Mar;95(2):373-84, viii. doi: 10.1016/j.mcna.2010.11.010. Review.

14.

Exenatide versus insulin glargine: a cost-effectiveness evaluation in patients with Type 2 diabetes in Switzerland.

Brändle M, Erny-Albrecht KM, Goodall G, Spinas GA, Streit P, Valentine WJ.

Int J Clin Pharmacol Ther. 2009 Aug;47(8):501-15.

PMID:
19640359
15.

Cost-effectiveness of insulin aspart versus human soluble insulin in type 2 diabetes in four European countries: subgroup analyses from the PREDICTIVE study.

Palmer JL, Goodall G, Nielsen S, Kotchie RW, Valentine WJ, Palmer AJ, Roze S.

Curr Med Res Opin. 2008 May;24(5):1417-28. doi: 10.1185/030079908X297295 . Epub 2008 Apr 8.

PMID:
18400145
16.
17.

[Pathophysiological conditions progressing from impaired glucose tolerance: type 2 diabetes mellitus].

Asakura T, Ito Y.

Nihon Rinsho. 2005 Feb;63 Suppl 2:237-41. Review. Japanese. No abstract available.

PMID:
15779378
18.

Cost-effectiveness of acarbose for the management of impaired glucose tolerance in Sweden.

Quilici S, Chancellor J, Maclaine G, McGuire A, Andersson D, Chiasson JL.

Int J Clin Pract. 2005 Oct;59(10):1143-52.

PMID:
16178980
19.

Options for intensifying diabetes treatment.

Reid TS.

J Fam Pract. 2011 Sep;60(9 Suppl):S7-10. No abstract available.

PMID:
21912777
20.

Therapy conversion to insulin detemir among patients with type 2 diabetes treated with oral agents: a modeling study of cost-effectiveness in the United States.

Valentine WJ, Erny-Albrecht KM, Ray JA, Roze S, Cobden D, Palmer AJ.

Adv Ther. 2007 Mar-Apr;24(2):273-90.

PMID:
17565917

Supplemental Content

Support Center